Aeglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes which have been engineered to have optimized catalytic and biopharmaceutic properties. The metabolic basis of tumor amino acid dependence is fundamentally different from the nutritional needs of normal tissues, creating a vulnerability to selective killing of tumor cells. Aeglea’s first two programs utilize enzymes that degrade either the amino acid L-methionine (Met) or L-arginine (Arg) for use as therapy in oncology. The Company's therapeutic strategy takes advantage of decades of clinical validation to leverage the genetic and epigenetic basis of tumor AA auxotrophy to identify patients likely to benefit from these molecules.
Type
Public
HQ
Austin, US
Founded
2013
Size (employees)
45 (est)+19%
Aeglea Biotherapeutics was founded in 2013 and is headquartered in Austin, US
Report incorrect company information

Key People/Management at Aeglea Biotherapeutics

M.B Anthony Quinn Ch.B, Ph.D

M.B Anthony Quinn Ch.B, Ph.D

Interim Chief Executive Officer
James Wooldridge M.D

James Wooldridge M.D

Chief Medical Officer
Charles N. York II, M.B.A

Charles N. York II, M.B.A

Chief Financial Officer
Aaron Schuchart M.B.A

Aaron Schuchart M.B.A

Chief Business Officer
Scott W. Rowlinson Ph.D

Scott W. Rowlinson Ph.D

Vice President of Research
M.S Joseph E. Tyler

M.S Joseph E. Tyler

Vice President of Manufacturing
Show more

Aeglea Biotherapeutics Office Locations

Aeglea Biotherapeutics has an office in Austin
Austin, US (HQ)
250 Barton Oaks Plaza One 901 S MoPac Expy
Show all (1)
Report incorrect company information

Aeglea Biotherapeutics Financials and Metrics

Aeglea Biotherapeutics Financials

USD

Net income (Q1, 2018)

(8.1 m)

EBIT (Q1, 2018)

(8.2 m)

Market capitalization (23-May-2018)

216.2 m

Closing share price (23-May-2018)

9.9

Cash (31-Mar-2018)

10.8 m
Aeglea Biotherapeutics's current market capitalization is $216.2 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

8.4 m10.1 m

R&D expense

18.1 m22.8 m

Operating expense total

26.5 m32.9 m

EBIT

(21.9 m)(27.7 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

1.8 m2.4 m2.1 m2.4 m2.4 m2.9 m

R&D expense

3.6 m4.4 m5.4 m4.9 m5.8 m6.9 m

Operating expense total

5.4 m6.9 m7.5 m7.3 m8.2 m9.8 m

EBIT

(4.6 m)(5.5 m)(6.3 m)(6.3 m)(6.7 m)(8.2 m)
Annual
USDFY, 2016FY, 2017

Cash

47.7 m12.8 m

Accounts Receivable

164.2 m

Inventories

1.7 m

Current Assets

66.4 m55 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

24 m70.6 m49.5 m16.8 m26.9 m10.8 m

Current Assets

35.2 m76.9 m71.7 m60.3 m66.2 m48.8 m

PP&E

321 k377 k342 k822 k802 k810 k

Total Assets

35.5 m77.3 m72.1 m61.3 m67.1 m49.8 m
Annual
USDFY, 2016FY, 2017

Net Income

(21.7 m)(27.2 m)

Depreciation and Amortization

132 k249 k

Inventories

(96.1 k)

Accounts Payable

(8 k)164 k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(4.5 m)(5.4 m)(6.2 m)(6.2 m)(8.1 m)

Depreciation and Amortization

70 k

Accounts Payable

509 k348 k523 k267 k396 k

Cash From Operating Activities

(7.4 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Aeglea Biotherapeutics Operating Metrics

FY, 2016

Nonclinical Development

3

Phase 1/2 Trials Products

1

Phase Approved

1

Phase I Trials Products

2
Show all operating metrics
Report incorrect company information